ReviewFrontiers in bioengineering and biotechnology2026
Genetic medicines for epilepsy: unlocking new avenues for seizure control.
Review in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy affects millions of people globally and is marked by unpredictable seizures due to excessive brain activity. These seizures not only vary widely in brain origin and severity but can also be associated with a range of factors - from head injuries to infections to genetic causes. Although antiseizure medications provide effective seizure control for many patients, approximately 30% experience drug-resistant epilepsy, with syndromic forms such as Lennox-Gastaut and Dravet syndrome posing significant therapeutic challenges. In addition, current pharmacological treatments are often associated with significant side effects and typically do not address the underlying pathophysiology. Gene therapies and genetic medicines are groundbreaking treatment modalities that enable direct targeting of disease mechanisms and associated genes. After FDA approval of the very first gene therapy in 2017 and the discovery of CRISPR-based gene editing, the field has rapidly expanded offering new hope for epilepsy treatment. This review highlights the latest advancements and therapeutic approaches for genetic medicines and explores their potential to transform the therapeutic landscape of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.